B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

168.02 +5.03 (+3.09%)
Delayed Quote Updated: 3:13 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
News headline image
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
From Guardant Health
Via Business Wire
News headline image
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
News headline image
Cathie Wood, Bullish On SpaceX Partner Velo3D, Buys More SPFR Shares, Adds Vertex On Dip ↗
Cathie Wood-led Ark Investment Management on Friday bought 25,000 shares, estimated to be worth about $250,000, in Jaws Spitfire Acquisition Corp (NYSE: SPFR), the blank-check... 
Via Benzinga
News headline image
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
From Guardant Health, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
News headline image
Guardant Health: Return On Capital Employed Insights ↗
In Q1, Guardant Health (NASDAQ:GH) posted sales of $78.67 million. Earnings were up 18.31%, but Guardant Health still reported an overall loss of $107.86 million. Guardant Health... 
Via Benzinga
News headline image
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Cathie Wood Buys $10.5M In Google, Loads Up Another $31.6M In Zoom ↗
Cathie Wood-led Ark Investment Management on Thursday bought 4,496 shares, estimated to be worth about $10.55 million, in Google parent Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG... 
Via Benzinga
News headline image
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer ↗
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras... 
Via Benzinga
News headline image
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021 ↗
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
News headline image
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
From Guardant Health, Inc.
Via Business Wire
News headline image
Cathie Wood Loads Up Another $292K In SpaceX Partner Velo3D's SPAC ↗
Cathie Wood-led Ark Investment Management on Wednesday bought 29,301 shares, estimated to be worth about $292,131, in the SPAC Jaws Spitfire Acquisition Corp (NYSE: SPFR)... 
Via Benzinga
News headline image
Where Guardant Health Stands With Analysts ↗
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 0 1... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 ↗
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
News headline image
Cathie Wood Buys Another $42M In Twitter Stock, Also Adds DraftKings, Netflix ↗
Cathie Wood-led Ark Investment Management on Monday bought 731,775 shares, estimated to be worth about $41.76 million, in Twitter Inc (NYSE: TWTR) — a day after The Bill and... 
Via Benzinga
News headline image
Cathie Wood Loads Up Yet Another $51M In Coinbase As Shares Slump Amid Bitcoin-Led Crypto Carnage ↗
Cathie Wood-led Ark Investment Management on Friday snapped up another 223,181 shares, worth about $50.7 million, in Coinbase Global Inc 
Via Benzinga
News headline image
With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble? ↗
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses. 
Via The Motley Fool
News headline image
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Exact Sciences Stock Soared Today ↗
The company's Cologuard DNA test appears to be in good shape to maintain its market leadership. 
Via The Motley Fool
News headline image
Guardant Had Colon Cancer Data, But Rival Exact Popped — Here's Why ↗
Guardant and Exact are in a "win-win situation," an analyst said Thursday as EXAS stock surged on a comparison to Guardant in colon cancer detection. 
Via Investor's Business Daily
News headline image
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
News headline image
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure ↗
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate? 
Via The Motley Fool
News headline image
3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming ↗
Falling costs are ushering in a new era of screening for a dreaded disease. 
Via The Motley Fool
News headline image
What 7 Analyst Ratings Have To Say About Guardant Health ↗
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1... 
Via Benzinga
News headline image
Guardant Health Inc (GH) Q1 2021 Earnings Call Transcript ↗
GH earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers T2 Biosystems (NASDAQ:TTOO) share... 
Via Benzinga
News headline image
Guardant Health Reports First Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.